143 related articles for article (PubMed ID: 11497208)
1. Ongoing trials of angiotensin-converting enzyme inhibition: what they can tell us.
Chalmers JP
Am J Hypertens; 2001 Aug; 14(8 Pt 2):270S-275S. PubMed ID: 11497208
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
Ferrari R
Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):15-29. PubMed ID: 15723572
[TBL] [Abstract][Full Text] [Related]
3. ACE inhibition in hypertension: focus on perindopril.
Cockcroft JR
Am J Cardiovasc Drugs; 2007; 7(5):303-17. PubMed ID: 17953470
[TBL] [Abstract][Full Text] [Related]
4. Specific properties and effect of perindopril in controlling the renin-angiotensin system.
Ferrari R; Pasanisi G; Notarstefano P; Campo G; Gardini E; Ceconi C
Am J Hypertens; 2005 Sep; 18(9 Pt 2):142S-154S. PubMed ID: 16125051
[TBL] [Abstract][Full Text] [Related]
5. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
6. Effect of the angiotensin-converting enzyme inhibitor perindopril on 24-hour blood pressure in patients with lacunar infarction: comparison between dippers and non-dippers.
Yamamoto Y; Oiwa K; Hayashi M; Ohara T; Muranishi M
Hypertens Res; 2005 Jul; 28(7):571-8. PubMed ID: 16335885
[TBL] [Abstract][Full Text] [Related]
7. The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition.
Harrap SB; Tzourio C; Cambien F; Poirier O; Raoux S; Chalmers J; Chapman N; Colman S; Leguennec S; MacMahon S; Neal B; Ohkubo T; Woodward M;
Hypertension; 2003 Sep; 42(3):297-303. PubMed ID: 12925557
[TBL] [Abstract][Full Text] [Related]
8. Role of perindopril in the prevention of stroke.
Papadopoulos DP; Votteas V
Recent Pat Cardiovasc Drug Discov; 2006 Nov; 1(3):283-9. PubMed ID: 18221093
[TBL] [Abstract][Full Text] [Related]
9. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
Rapezzi C; Ciliberti P; Graziosi M; Riva L
Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
[TBL] [Abstract][Full Text] [Related]
10. The Perindopril Protection Against Recurrent Stroke Study (PROGRESS): clinical implications for older patients with cerebrovascular disease.
Ratnasabapathy Y; Lawes CM; Anderson CS
Drugs Aging; 2003; 20(4):241-51. PubMed ID: 12641480
[TBL] [Abstract][Full Text] [Related]
11. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.
PROGRESS Collaborative Group
Lancet; 2001 Sep; 358(9287):1033-41. PubMed ID: 11589932
[TBL] [Abstract][Full Text] [Related]
12. Evidence for benefits of perindopril in hypertension and its complications.
Laurent S
Am J Hypertens; 2005 Sep; 18(9 Pt 2):155S-162S. PubMed ID: 16125052
[TBL] [Abstract][Full Text] [Related]
13. PROGRESS - Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Progress Management Committee.
J Hypertens; 1999 Nov; 17(11):1647-55. PubMed ID: 10608480
[TBL] [Abstract][Full Text] [Related]
14. Perindopril: an updated review of its use in hypertension.
Hurst M; Jarvis B
Drugs; 2001; 61(6):867-96. PubMed ID: 11398915
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.
Brugts JJ; Ferrari R; Simoons ML
Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):345-60. PubMed ID: 19379059
[TBL] [Abstract][Full Text] [Related]
16. The ASCOT trial: clarifying the role of ACE inhibition in the reduction of cardiovascular events in patients with hypertension.
Meurin P
Am J Cardiovasc Drugs; 2006; 6(5):327-34. PubMed ID: 17083267
[TBL] [Abstract][Full Text] [Related]
17. RAS inhibitors' dose-dependent efficacy: myth or reality?
Taddei S
Curr Med Res Opin; 2015; 31(7):1245-56. PubMed ID: 25985327
[TBL] [Abstract][Full Text] [Related]
18. [ADVANCE study: objectives, design and current status].
Chalmers J
Drugs; 2003; 63 Spec No 1():39-44. PubMed ID: 12708881
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular events in hypertension trials of Angiotensin-converting enzyme inhibitors.
Elliott WJ
J Clin Hypertens (Greenwich); 2005 Aug; 7(8 Suppl 2):2-4. PubMed ID: 16106130
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
